APP and Alzheimer disease: While basal levels of 4E‐BP2 and FMRP were not altered in APP/PS1 mice (Figure S1), our findings warrant future mechanistic investigation into how these multiple dysregulated pathways converge to trigger AD‐linked symptoms.